There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
NCT04996875
Recruiting
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
Register for Updates
Quality of Life and Function of Patients With Pelvic Tumors After Undergoing Hemipelvectomy
NCT05134142
Recruiting
This study aims to determine the functional outcomes of patients who underwent internal hemipelvectomy with or without reconstruction or external hemipelvectomy for pelvic tumors. Learning about the outcomes of these patients may help researchers determine the long-term effects of different types of hemipelvectomy procedures and may help improve quality of life.
Gender:
ALL
Ages:
All
Trial Updated:
05/29/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Malignant Primary Pelvic Neoplasm
Register for Updates
Pimavanserin for Insomnia in Veterans With PTSD
NCT05441280
Recruiting
This is a preliminary randomized, double-blind, placebo-controlled trial comparing pimavanserin 34mg at bedtime vs. placebo for the treatment of insomnia associated with post-traumatic stress disorder.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/29/2025
Locations: Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas
Conditions: Post-traumatic Stress Disorder, Insomnia
Register for Updates
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387
Recruiting
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/29/2025
Locations: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas +4 locations
Conditions: Plasma Cell Myeloma
Register for Updates
Prophylactic Lymphovenous Bypass Procedure Following Inguinal Lymphadenectomy: A Prospective Observational Study
NCT05992909
Recruiting
To learn if LBP can help to prevent lymphedema when it is performed at the time of surgery rather than after a patient has already developed the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphadenectomy
Register for Updates
Study of Olverembatinib (HQP1351) in Patients With CP-CML
NCT06423911
Recruiting
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/29/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Myeloid Leukemia, CML, CML, Chronic Phase
Register for Updates
Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy
NCT06680479
Recruiting
A5422 is a phase 1, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and immunogenicity of a vaccination with stabilized CH505 TF chTrimer admixed with 3M-052-AF + Aluminum hydroxide (Alum), to assess the effect of CH505 TF chTrimer vaccine as a therapeutic vaccine in adults living with HIV-1 on suppressive antiretroviral therapy (ART) with the aim of inducing new HIV-1 Envelope (Env) B-cell neutralizing immune responses. Participants will be on stu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Houston Advancing Research Team CRS, Houston, Texas
Conditions: HIV-1
Register for Updates
Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention
NCT07010315
Recruiting
To develop and test liver cancer prevention educational material.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Liver Cancer
Register for Updates
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608
Recruiting
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Non-Small Cell Lung Cancer
Register for Updates
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118
Recruiting
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 prior lines of therapies. The study will consist of 3 parts. Part A monotherapy dose escalation. Part B dose optimisation. Part C Dose expansion at the recommended phase 2 dose (RP2D)
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/28/2025
Locations: Research Site, Houston, Texas
Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Register for Updates
Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
NCT06560632
Recruiting
This is a multicenter, open-label Phase 1 trial to investigate the safety, PK, and pharmacodynamics of the Polθ inhibitor RP-3467 alone or in combination with the poly-ADP ribose polymerase inhibitor (PARPi) olaparib in adults with molecularly selected advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: # 1001, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor
Register for Updates
Esprit BTK Post-Approval Study
NCT06656364
Recruiting
The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Park Plaza Hospital, Houston, Texas
Conditions: Chronic Limb-Threatening Ischemia
Register for Updates